Arch Fam Med
Institution: CLOCKSS  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 3 No. 2, February 1994 TABLE OF CONTENTS
 • Online Features
  Clinical Reviews
 This Article
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Cefuroxime Axetil in the Treatment of Sinusitis

A Review

Gary E. Paker, PharmD; James A. Graham, PharmD; Alan M. Rauch, MD; Jeffrey J. Collins, PhD

Arch Fam Med. 1994;3(2):165-175.

Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.

1. Friedman RA, Harris JP. Sinusitis. Annu Rev Med. 1991;42:471-489. PUBMED
2. Wald ER, Guerra N, Byers C. Upper respiratory tract infections in young children: duration of and frequency of complications. Pediatrics. 1991;87:129-133. FREE FULL TEXT
3. Druce HM. Emerging techniques in the diagnosis of sinusitis. Ann Allergy. 1991;66:132-136. PUBMED
4. Evans FO, Sydnor JB, Moore WEC. Sinusitis of the maxillary antrum. N Engl J Med. 1975;293:735-739. PUBMED
5. Hamory BH, Sande MA, Sydnor A, Seal DL, Gwaltney JM. Etiology and antimicrobial therapy of acute maxillary sinusitis. J Infect Dis. 1979;139:197-202. FREE FULL TEXT
6. Smith BR, LeFrock JL. Cefuroxime: antimicrobial activity, pharmacology, and clinical efficacy. Ther Drug Monit. 1983;5:149-160. PUBMED
7. Gold B, Rodriguez WJ. Cefuroxime: mechanisms of action, antimicrobial activity, pharmacokinetics, clinical applications, adverse reactions, and therapeutic indications. Pharmacotherapy. 1983;3:82-100. PUBMED
8. Ahmad F, McLeod DT, Croughan MJ, Calder MA. Antimicrobial susceptibility of Branhamella catarrhalis isolates from bronchopulmonary infections. Antimicrob Agents Chemother. 1984;26:424-425. FREE FULL TEXT
9. Angehrn P, Hohl P, Hubschwerlen C, Page M, Then R. Antibacterial properties of Ro 40-6890, a broad-spectrum cephalosporin, and its novel orally absorbable ester, Ro 41-3399. Antimicrob Agents Chemother. 1992;36:2825-2834. FREE FULL TEXT
10. Chamberland S, L'Ecuyer J, Lessard C, et al. Antibiotic susceptibility profiles of 941 gramnegative bacteria isolated from septicemic patients throughout Canada. Clin Infect Dis. 1992;15:615-628. FREE FULL TEXT
11. Chin NX, Gu JW, Neu HC. In vitro activity of cefacanel versus other oral cephalosporins. Eur J Clin Microbiol Infect Dis. 1991;10:676-682. PUBMED
12. Doern GV, Tubert TA. In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis. Diagn Microbiol Infect Dis. 1990;13:349-352. PUBMED
13. Doern GV, Vautour R. In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae. Diagn Microbiol Infect Dis. 1992;15:633-640. PUBMED
14. George MJ, Kitch B, Henderson FW, Gilligan PH. In vitro activity of orally administered antimicrobial agents against Haemophilus influenzae recovered from children monitored longitudinally in a group day-care center. Antimicrob Agents Chemother. 1991;35:1960-1964. FREE FULL TEXT
15. James NC, Donn KH, Collins JJ, et al. Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens. Antimicrob Agents Chemother. 1991;35:1860-1863. FREE FULL TEXT
16. Jones RN, Barry AL. Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Antimicrob Agents Chemother. 1988;32:443-449. FREE FULL TEXT
17. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990;34:2075-2080. FREE FULL TEXT
18. Van Landuyt HW, Boelaert J, Piot P, Verbist L. In vitro activity of temocillin against clinical isolates. Drugs. 1985;29(suppl_5):1-8. PUBMED
19. Mendelman PM, Henritzy LL, Chaffin DO, et al. In vitro activities and targets of three cephem antibiotics against Haemophilus influenzae. Antimicrob Agents Chemother. 1989;33:1878-1882. FREE FULL TEXT
20. Murray PR, Jones RN, Allen SD, Erwin ME, Fuchs PC, Gerlach EH. Multilaboratory evaluation of the in vitro activity of 13 β-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria. Diagn Microbiol Infect Dis. 1993;16:191-203. PUBMED
21. Nord CE, Rylander M, Norrby SR. Susceptibility of anaerobic bacteria to BAY v 3522. Antimicrob Agents Chemother. 1991;35:594-599. FREE FULL TEXT
22. Riess G, Andrews J, Thornber D, Wise R. In vitro activity of RU 29246, the active compound of the cephalosporin prodrug ester HR 916. Antimicrob Agents Chemother. 1992;36:2360-2364. FREE FULL TEXT
23. Ritchie DJ, Hopefl AW, Milligan TW, Byrne JE, Maddux MS. In vitro activity of clarithromycin, cefprozil, and other common oral antimicrobial agents against gram-positive and gramnegative pathogens. Clin Ther. 1993;15:107-113. PUBMED
24. Scriver SR, Willey BM, Low DE. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens. Eur J Clin Microbiol Infect Dis. 1992;11:646-652. PUBMED
25. Shelton MM, Welch DF. Antimicrobial activities and susceptibility testing considerations of ampicillin, cephalothin, cefaclor, and cefuroxime against invasive isolates of Haemophilus influenzae. Chemotherapy (Basel). 1989;35:88-94.
26. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibility of 170 penicillin-susceptible and -resistant pneumococci to cefdinir, cefpodoxime, cefaclor, cefuroxime and cefixime. Presented at the 92nd General Meeting of the American Society of Microbiology; May 26, 1992; New Orleans, La.
27. Wise R, Andrews JM, Ashby JP, Thornber D. In vitro activity of Bay v 3522, a new cephalosporin, compared with activities of other agents. Antimicrob Agents Chemother. 1990;34:813-818. FREE FULL TEXT
28. Appelbaum PC. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria. J Antimicrob Chemother. 1993;31(suppl A):29-38. FREE FULL TEXT
29. Appelbaum PC, Spangler SK, Shiman R, Jacobs MR. Susceptibilities of 540 anaerobic gramnegative bacilli to amoxicillin, amoxicillin-BRL 42715, amoxicillin-clavulanate, temafloxacin, and clindamycin. Antimicrob Agents Chemother. 1992;36:1140-1143. FREE FULL TEXT
30. Brown EM. The in-vitro susceptibility of the Bacteroides fragilis group to amoxycillin-clavulanic acid. J Antimicrob Chemother. 1984;14:367-372. FREE FULL TEXT
31. Doern GV, Vautour R, Parker D, Tubert T, Torres B. In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother. 1991;35:1504-1507. FREE FULL TEXT
32. Farrell ID, Brookes GR, Ball AP, Geddes AM. Laboratory efficacy of amoxicillin and clavulanic acid combinations and its correlation with the clinical response to treatment. In: Nelson JD, Grassi GG, eds. Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy on Current Chemotherapy and Infectious Disease, October 1-5, 1979. Washington, DC: American Society of Microbiology; 1980: 351-352.
33. Leigh DA, Marriner JM, Freeth M, Bradnock K, Nisbet D. Antibacterial activity of Augmentin and treatment of tissue infections. In: Rolinson GN, Watson A, eds. Proceedings of the First Symposium on Augmentin: Clavulanate-potentiated Amoxycillin, July 3-4, 1980. Amsterdam, the Netherlands: Excerpta Medica; 1980:222-230.
34. Qadri SMH, Ueno Y, Postle G, San Pedro J. Comparative evaluation of GR 69153, a catecholsubstituted cephalosporin. Drug Invest. 1993;5:80-85.
35. Fuchs PC, Barry AL, Thornsberry C, Gavan TL, Jones RN. In vitro evaluation of Augmentin by both microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretative criteria, and quality control limits. Antimicrob Agents Chemother. 1983;24:31-38. FREE FULL TEXT
36. Hohl P, Zollinger-lten J, von Graevenitz A. In vitro activities of Ro 40-6890 and 164 predominantly intestinal members of the families Enterobacteriaceae and Vibrionaceae. Antimicrob Agents Chemother. 1992;36:2835-2838. FREE FULL TEXT
37. Visser MR, Rozenberg-Arska M, Beumer H, Hoepelman IM, Verhoef J. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Antimicrob Agents Chemother. 1991;35:858-868. FREE FULL TEXT
38. Wexler HM, Molitoris E, Finegold SM. In vitro activities of three of the newer quinolones against anaerobic bacteria. Antimicrob Agents Chemother. 1992;36:239-243. FREE FULL TEXT
39. Fung CP, Powell M, Seymour A, Yuan M, Williams JD. The antimicrobial susceptibility of Moraxella catarrhalis isolated in England and Scotland in 1991. J Antimicrob Chemother. 1992;30:47-55. FREE FULL TEXT
40. Mazzulli T, Simor AE, Jaeger R, Fuller S, Low DE. Comparative in vitro activities of several new fluoroquinolones and β-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1990;34:467-469. FREE FULL TEXT
41. Miyazaki S, Miyazaki Y, Tsuji A, Nishida M, Goto S. In vitro antibacterial activity of ME1207, a new oral cephalosporin. Antimicrob Agents Chemother. 1991;35:1691-1694. FREE FULL TEXT
42. Willey B, Scriver SR, Simor AE. Comparative in vitro activity of a new cephalosporin, cefdinir (CI-983), against common respiratory pathogens. Presented at the 92nd General Meeting of the American Society of Microbiology; May 26, 1992; New Orleans, La.
43. Howard AJ, Dunkin KT. Comparative in-vitro activity of a new oral carbacephem, LY 163892. J Antimicrob Chemother. 1988;22:445-456. FREE FULL TEXT
44. Jones RN. Preliminary in-vitro studies of BMY28232, the active metabolite of the BMY-28271 cephalosporin ester. J Antimicrob Chemother. 1989;23:654-656. FREE FULL TEXT
45. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother. 1992;26:46-55. ABSTRACT
46. Bauerfeind A. In-vitro activity of dirithromycin in comparison with other new and established macrolides. J Antimicrob Chemother. 1993;31(suppl C):39-49. FREE FULL TEXT
47. Chin NX, Neu HC. In vitro activity of MC-352, a new 16-membered macrolide. Antimicrob Agents Chemother. 1992;36:1699-1702. FREE FULL TEXT
48. Neal TJ, O'Donoghue MAT, Ridgway EJ, Allen KD. In-vitro activity of ten antimicrobial agents against penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1992;30:39-46. FREE FULL TEXT
49. Peters DH, Clissold SP. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992;44:117-164. PUBMED
50. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm. 1992;11:137-152. PUBMED
51. Cohen MA, Huband MD, Mailloux GB, et al. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent. Antimicrob Agents Chemother. 1991;35:141-146. FREE FULL TEXT
52. Engquist S, Nord CE, Puhakka HJ, et al. Loracarbef versus doxycycline in the treatment of acute bacterial maxillary sinusitis. J Antimicrob Chemother. 1993;31:949-961. FREE FULL TEXT
53. Robbins M. Marais R, Felmingham D, Ridgway GL. The in-vitro activity of doxycycline and minocycline against anaerobic bacteria. J Antimicrob Chemother. 1987:20:379-382. FREE FULL TEXT
54. Cao C, Chin NX, Neu HC. In-vitro activity and β-lactamase stability of LY163892. J Antimicrob Chemother. 1988;22:155-165. FREE FULL TEXT
55. Doern G. In vitro activity of loracarbef and effects of susceptibility test methods. Am J Med. 1992;92(suppl 6A):7S-15S. PUBMED
56. Fass RJ. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother. 1983;24:568-574. FREE FULL TEXT
57. Wust J, Wilkins TD. Susceptibility of anaerobic bacteria to sulfamethoxazole/trimethoprim and routine susceptibility testing. Antimicrob Agents Chemother. 1978;14:384-390. FREE FULL TEXT
58. Ceftin® (cefuroxime axetil) tablets package insert. In: Schumacher MM, ed. Physicians' Desk Reference. 47th ed. Montvale, NJ: Medical Economics Data; 1993:577-578.
59. Maeyama T, Furuta S, Monyamaa I, et al. Fundamental and clinical studies on cefuroxime axetil (CXM-AX) in otorhinolaryngological field [in Japanese]. Chemotherapy (Tokyo). 1986;34:1078-1089.
60. Sudderick RM, Lund VJ, Thomson JP, McCombe A, Mackay IS. An evaluation of the penetration of cefuroxime axetil into human paranasal sinus tissue. Rhinology. 1992;30:11-16. PUBMED
61. Aguedas AG, Arrieta AC, Stutman HR, Akaniro JC, Marks MI. In vitro activity of cefprozil (BMY 28100) and loracarbef (LY163892) against pathogens obtained from middle ear fluid. J Antimicrob Chemother. 1991;27:311-318. FREE FULL TEXT
62. Knapp CC, Washington JA II. In vitro activities of LY163892, cefaclor, and cefuroxime. Antimicrob Agents Chemother. 1988;32:131-133. FREE FULL TEXT
63. Doern GV. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarrhalis. Diagn Microbiol Infect Dis. 1991;14:75-77. PUBMED
64. Finn AL, Straughn A, Meyer M, Chubb JM. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dispos. 1987;8:519-526. PUBMED
65. Paavolainen M, Kohonen A, Palva T, Renkonen AV. Penetration of erythromycin stearate into maxillary sinus mucosa and secretion in chronic maxillary sinusitis. Acta Otolaryngol. 1977;84:292-295. PUBMED
66. Griffiths GK, VandenBurg MJ, Wight LJ, Gudgeon AC, Kelsey M. Efficacy and tolerability of cefuroxime axetil in patients with upper respiratory tract infections. Curr Med Res Opin. 1987;10:555-567. PUBMED
67. Carbon C, Bons J, Georges D. Prospective study of the clinical tolerance of a new oral antibiotic: cefuroxime axetil [in French]. Therapie. 1988;43:369-372. PUBMED
68. Gastpar H. Management of ear nose and throat infections in the community. In: Adam D, ed. Cefuroxime Axetil-A Significant Advance in the Treatment of Infection: A Symposium Report Based on the 2nd Biennial Conference of Infectious Diseases and Malignancies, Montreux Convention and Exhibition Centre; March 6, 1989; Montreux, France. Surrey, England: Medical Action Communications; September 1989:11-14.
69. Gehanno P, Boucot I, Pappo M, Chiche D, Berche P. Efficacy and tolerance of cefuroximeaxetil in the treatment of community-acquired acute sinusitis. In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 21-24, 1990; Atlanta, Ga. Abstract 1345.
70. Lund VJ, Whittet H. Cefuroxime axetil: management of adult sinusitis in the clinic. J Chemother. 1989;(suppl 4):763-764.
71. Marcucci L, Paternesi A. Infections of the upper respiratory tract: Italian clinical trial on the use of cefuroxime axetil [in Italian]. Riv Patalogia Sperimentazione Clinica. 1990;30:19-26.
72. Brodie DP, Knight S, Cunningham K. Comparative study of cefuroxime axetil and amoxycillin in the treatment of acute sinusitis in general practice. J Int Med Res. 1989;17:547-551. PUBMED
73. Camacho AE, Cobo R, Otte J, et al. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis. Am J Med. 1992;93:271-276. PUBMED
74. Hebblethwaite EM, Brown GW, Cox DM. A comparison of the efficacy and safety of cefuroxime axetil and Augmentin in the treatment of upper respiratory tract infections. Drugs Exp Clin Res. 1987;13:91-94. PUBMED
75. Roge J, Durand B, Pappo M. Treatment of ENT infections with cefuroxime axetil: comparative study versus an amoxycillin/clavulanic acid combination in specialized general practice [in French]. J Fr Oto-Rhino-Laryngol. 1989;38:138-143.
76. Stahl JP, Pappo M. A multicenter randomized trial of cefuroxime-axetil versus amoxicillin with clavulanic acid in community-acquired ENT and lower respiratory tract infections [in French]. Sem Hop Paris. 1989;65:247-251.
77. Tremblay C, Dubois J, Guertin L. A randomized comparison of the efficacy and safety of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute maxillary sinusitis. In: Program and abstracts of the 8th Mediterranean Congress of Chemotherapy; May 24-29, 1990; Athens, Greece. Abstract 214.
78. Sydnor A Jr, Gwaltney JM Jr, Cocchetto DM. Scheid WM. Comparative evaluation of cefuroxime axetil and cefaclor for treatment of acute bacterial maxillary sinusitis. Arch Otolaryngol Head Neck Surg. 1989;115:1430-1433. FREE FULL TEXT
79. Freche C, Fombeur JP, Pappo M. Evaluation of cefuroxime-axetil in the treatment of acute sinusitis in adults: comparative study with cefaclor [in French]. Therapie. 1988;43(suppl):365-368. PUBMED
80. Dupuis G, Ebbo D, Evennou A, Pappo M. Efficacy and safety of cefuroxime-axetil for the trearment of upper respiratory tract infections: results of a randomized trial vs cefadroxil [in French]. Rev Laryngol. 1989;110:123-126.
81. Gehanno P, Boucot I, Chiche D, Berche P. Treatment of community acquired acute sinusitis: cefuroxime axetil vs cefixime [in French]. Med Mal Infect. 1991;21:61-65.
82. Petrikkos G, Moschovakis E, Lambrinopoulou E. Anagnostou E. Chrysouli Z. Giamarellou H. Comparative efficacy of clarithromycin and cefuroxime axetil in acute exacerbation of chronic sinusitis. In: Program and abstracts of the 8th Mediterranean Congress of Chemotherapy: May 24-29, 1992; Athens, Greece. Abstract 719.
83. Schlenter WW. Cefuroxime axetil versus doxycycline in the treatment of sinusitis. In: Program and abstracts of the 17th International Congress of Chemotherapy; June 23-28, 1991; Berlin, Germany. Abstract 1267.
84. Giebink GS. Criteria for evaluation of antimicrobial agents and current therapies for acute sinusitis in children. Clin Infect Dis. 1992;14(suppl 2):S212-S215. PUBMED
85. Sydnor A Jr, Gwaltney JM, Scheid WM. The aetiology and antimicrobial treatment of acute maxillary sinusitis in adults. In: Phillips I, ed. Issues in the Treatment of Upper Respiratory Tract Infections. London, England: Royal Society of Medicine Services; 1988:31-39. International Congress and Symposium Series, No. 130.
86. Augmentin® (amoxicillin/clavulanate potassium) tablets, powder for oral suspension and chewable tablets package insert. In: Schumacher MM, ed. Physicians' Desk Reference. 47th ed. Montvale, NJ: Medical Economics Data; 1993: 2289-2291.
87. Chin NX, Gu JW, Neu HC. In vitro activity of cefacanel versus other oral cephalosporins. Eur J Clin Microbiol Infect Dis. 1991;10:676-682. PUBMED
88. Wise R, Andrews JM, Ashby JP, Thornber D. Ceftibuten: a new orally absorbed cephalosporin: in vitro activity against strains from the United Kingdom. Diagn Microbiol Infect Dis. 1991;14:45-52. PUBMED
89. Brogden RN, Campoli-Richards DM. Cefixime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1989;38:524-550. PUBMED
90. Jorgensen JH, Crawford SA. Alexander GA. Comparison of moxalactam (LY 127935) and cefotaxime against anaerobic bacteria. Antimicrob Agents Chemother. 1980;17:901-904. FREE FULL TEXT
91. Chow AW, Bartlett KH. Comparative in vitro activity of ceftazidime (GR-20263) and other β-lactamase stable cephalosporins against anaerobic bacteria. J Antimicrob Chemother. 1981;8(suppl B):91-95. FREE FULL TEXT
92. Biaxin (clarithromycin) Filmtab® tablets package insert. In: Schumacher MM, ed. Physicians' Desk Reference. 47th ed. Montvale, NJ: Medical Economics Data; 1993:505-507.
93. Anonymous; Rangell MS, ed. 1993 Red Book. Montvale, NJ: Medical Economics Data; 1993:97-98, 114, 133, 155, 222-224, 532, 536, 570.